Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells

Laboratory Investigation

Volumn 88, Issue 7, 2008, Pages 731-739

  Kato, Hideki ^a,b   Ishida, Junji ^a   Nagano, Katsumasa ^a   Honjo, Kaori ^a   Sugaya, Takeshi ^a   Takeda, Norifumi ^b   Sugiyama, Fumihiro ^a   Yagami, Ken Ichi ^a   Fujita, Toshiro ^b   Nangaku, Masaomi ^b   Fukamizu, Akiyoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II type 1 receptor; Atherosclerosis; Bone marrow transplantation; Kidney injury; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; MESSENGER RNA; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; KIDNEY INJURY; KNOCKOUT MOUSE; LETHALITY; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; AORTA; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; KIDNEY; MACROPHAGES, PERITONEAL; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ANGIOTENSIN, TYPE 1; SPLEEN;

EID: 46049104184     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.42     Document Type: Article

References (39)

1. Crowley SD, Tharaux PL, Audoly LP, et al. Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 2004;181:561-570.
2. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
3. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002;15(1 Part 2):9S-13S.
4. Wassmann S, Czech T, van Eickels M, et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004;110:3062-3067.
5. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-1817.
6. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:P3-P13.
7. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001;38:1382-1387.
8. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005;14:125-131.
9. Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999;104:1693-1701.
10. Kranzhofer R, Browatzki M, Schmidt J, et al. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999;257:826-828.
11. Keidar S, Heinrich R, Kaplan M, et al. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 2001;21:1464-1469.
12. Keidar S, Kaplan M, Hoffman A, et al. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995;115:201-215.
13. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997;272:21609-21615.
14. Yanagitani Y, Rakugi H, Okamura A, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999;33(1 Part 2):335-339.
15. Hahn AW, Jonas U, Buhler FR, et al. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994;347:178-180.
16. Muller DN, Shagdarsuren E, Park JK, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002;161:1679-1693.
17. Nahmod KA, Vermeulen ME, Raiden S, et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003;17:491-493.
18. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin- converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-1541.
19. Fukamizu A, Sugimura K, Takimoto E, et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993;268:11617-11621.
20. Sugiyama F, Haraoka S, Watanabe T, et al. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest 1997;76:835-842.
21. Shimokama T, Haraoka S, Horiguchi H, et al. The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: development of lesions and morphometric analysis. Virchows Arch 1998;432:169-175.
22. Sugaya T, Nishimatsu S, Tanimoto K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995;270:18719-18722.
23. Hisada Y, Sugaya T, Tanaka S, et al. An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury. Lab Invest 2001;81:1243-1251.
24. Kato H, Ishida J, Imagawa S, et al. Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J 2005;19:2023-2025.
25. Hartner A, Cordasic N, Klanke B, et al. The alpha8 integrin chain affords mechanical stability to the glomerular capillary tuft in hypertensive glomerular disease. Am J Pathol 2002;160:861-867.
26. Kim JG, Keshava C, Murphy AA, et al. Fresh mouse peritoneal macrophages have low scavenger receptor activity. J Lipid Res 1997;38:2207-2215.
27. Kaushik N, Fear D, Richards SC, et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005;58:826-832.
28. Korostynski M, Kaminska-Chowaniec D, Piechota M, et al. Gene expression profiling in the striatum of inbred mouse strains with distinct opioid-related phenotypes. BMC Genomics 2006;7:146.
29. Rodgers KE, Xiong S, Steer R, et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000;18:287-294.
30. Zhou Y, Chen R, Catanzaro SE, et al. Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. Am J Hypertens 2005;18(4 Part 1):486-492.
31. Nishijo N, Sugiyama F, Kimoto K, et al. Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab Invest 1998;78:1059-1066.
32. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105:1605-1612.
33. Nishida M, Fujinaka H, Matsusaka T, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002;110:1859-1868.
34. Fukuda D, Sata M, Ishizaka N, et al. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008;28:90-96.
35. Yamada T, Kondo T, Numaguchi Y, et al. Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells. Arterioscler Thromb Vasc Biol 2007;27:2363-2369.
36. Cassis LA, Rateri DL, Lu H, et al. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 2007;27:380-386.
37. Lu H, Rateri DL, Feldman DL Jr RJ, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-993.
38. Ohtani K, Suzuki Y, Eda S, et al. The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J Biol Chem 2001;276:44222-44228.
39. Chen Y, Sankala M, Ojala JR, et al. A phage display screen and binding studies with acetylated low density lipoprotein provide evidence for the importance of the scavenger receptor cysteine-rich (SRCR) domain in the ligand-binding function of MARCO. J Biol Chem 2006;281:12767-12775.